Compare PX & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PX | WVE |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2015 |
| Metric | PX | WVE |
|---|---|---|
| Price | $9.86 | $16.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | $15.70 | ★ $29.44 |
| AVG Volume (30 Days) | 516.9K | ★ 13.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 35.89 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $301,314,000.00 | $109,230,000.00 |
| Revenue This Year | $2.80 | N/A |
| Revenue Next Year | $18.77 | $31.09 |
| P/E Ratio | $71.63 | ★ N/A |
| Revenue Growth | 9.77 | ★ 103.75 |
| 52 Week Low | $8.68 | $5.28 |
| 52 Week High | $13.93 | $21.73 |
| Indicator | PX | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 63.98 |
| Support Level | $9.91 | $15.23 |
| Resistance Level | $10.29 | $17.41 |
| Average True Range (ATR) | 0.33 | 1.83 |
| MACD | 0.04 | 0.22 |
| Stochastic Oscillator | 45.67 | 61.52 |
P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.